MedPath

Text Message Intervention to Improve Adherence in Adolescents and Young Adults With Celiac Disease

Not Applicable
Completed
Conditions
Celiac Disease
Interventions
Behavioral: Educational Text Message Reminders
Registration Number
NCT02458898
Lead Sponsor
Stanford University
Brief Summary

This is a prospective randomized controlled trial investigating the impact of educational bidirectional text message reminders on gluten free diet adherence among adolescents and young adults with celiac disease age 12-24. Participants will complete a series of online questionnaires assessing quality of life, patient activation, celiac symptoms, and self reported dietary adherence at the beginning and end of the study. Participants will also have their blood drawn to measure Tissue Transglutaminase IgA (TTG IgA) antibody and Deamidated Gliadin Peptide IgA (DGP IgA) at the beginning and end of the study. Lab draws can be done locally, and are at no cost to the participant. Patients are randomized to the intervention or control group based on enrollment TTG IgA. Intervention group receives 45 unique text messages over the 3 month study. A gift card is provided for participation in the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
61
Inclusion Criteria
  • Age 12-24
  • Celiac disease diagnosed by a gastroenterologist at least 1 year prior to enrollment
  • Participant with ability to read email and text messages in English
  • Access to a mobile phone
  • Unlimited text messaging plan or agreement to receive 45 text messages for the study
Read More
Exclusion Criteria
  • Participant inability to answer survey questions and text prompts in English
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Text Message InterventionEducational Text Message RemindersA series of 45 unique educational text messages sent over a period of 3 months in the evenings. Text messages include humorous reminders, links to online celiac disease resources, and bidirectional questions.
Primary Outcome Measures
NameTimeMethod
Tissue Transglutaminase IgA (TTG IgA)3 months

Percent change in TTG IgA for each participant pre and post study period

Secondary Outcome Measures
NameTimeMethod
Patient-reported celiac disease symptom measure (CDI) score3 months

Change in patient-reported celiac disease symptom measure (CDI) questionnaire score pre and post study period

Patient-reported dietary adherence (CDAT) score3 months

Change in patient-reported dietary adherence (CDAT) questionnaire score pre and post study period

Deamidated Gliadin Peptide IgA (DGP IgA)3 months

Percent change in DGP IgA for each participant pre and post study period

Patient Activation Measure (PAM) score3 months

Change in Patient Activation Measure (PAM) questionnaire score pre and post study period

NIH-PROMIS quality of life score3 months

Change in NIH-PROMIS quality of life questionnaire score pre and post study period

Trial Locations

Locations (1)

Stanford University Pediatric Gastroenterology Department

🇺🇸

Palo Alto, California, United States

© Copyright 2025. All Rights Reserved by MedPath